From Guideline to Clinical Practice: Towards an Era Without Surgical Site Infections [0.03%]
从指南到临床实践：向无手术部位感染时代迈进
Benedikt Kaufmann,André Mihaljevic
Benedikt Kaufmann
TNF Inhibitor-Induced Sarcoidosis-Like Lesions in Inflammatory Bowel Disease [0.03%]
克罗恩病和溃疡性结肠炎患者使用肿瘤坏死因子拮抗剂与类肉芽肿病变关系的研究
Zlata Chkolnaia,Benedicte Lebrun-Vignes,Aurelien Amiot et al.
Zlata Chkolnaia et al.
Background: While tumor necrosis factor (TNF) inhibitors can induce paradoxical reactions, sarcoidosis-like disease has hardly been reported so far. This study aimed to describe the epidemiological, diagnostic and therape...
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry [0.03%]
基于ENEIDA登记的数据的老年患者术后克罗恩病的管理及结局的比较研究
Míriam Mañosa,Margalida Calafat,Elena Ricart et al.
Míriam Mañosa et al.
Background: Limited data are available on the management and outcomes of postoperative Crohn's disease (CD) in older patients. We aimed to describe the management of CD in the postoperative setting and assess surgical pos...
Promoting Well-Being Among Gastroenterologists - A Call for Systemic Action [0.03%]
促进胃肠病学家的福祉——系统行动的呼吁
Katharina Zimmermann,Iago Rodríguez-Lago,Reena Sidhu et al.
Katharina Zimmermann et al.
United European Gastroenterology (UEG) has launched an initiative to promote physician well-being and prevent burnout. This current concept article is based on a survey of the National Societies Forum and National Societies Committee, a met...
Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry [0.03%]
Filgotinib是一种有效且安全的治疗难治性溃疡性结肠炎的方案：来自荷兰克罗恩病和结肠炎（ICC）登记处的真实世界证据
M R Naber,A E van der Meulen,P W Voorneveld et al.
M R Naber et al.
Background: Filgotinib is a preferential Janus kinase 1 (JAK-1) inhibitor registered for the treatment of ulcerative colitis (UC). Real-world effectiveness of filgotinib, especially for difficult-to-treat (DTT, failure of...
Should Elective TIPS be Placed in Non-Abstinent Patients With Alcohol-Related Cirrhosis? [0.03%]
酒精性肝硬化非戒酒患者可选择进行TIPS手术吗？
Marika Rudler,Dominique Thabut
Marika Rudler
Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy [0.03%]
长效干扰素联合替诺福韦治疗丁肝96周后的10年随访（HIDIT-II）：联合治疗改善临床结局
Cihan Yurdaydin,Julia Kahlhöfer,Florin Alexandru Caruntu et al.
Cihan Yurdaydin et al.
Background: Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon-alfa-2a (PEG-IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The ...
Patient-Reported-Outcome-Measures (PROMs) After Gastrointestinal Endoscopic Resections [0.03%]
内镜黏膜下剥离术后患者报告结果指标(PROMs)分析
Laura Retzbach,Karl-Hermann Fuchs,Markus Brand et al.
Laura Retzbach et al.
Background: Data on patient-reported outcome measures (PROMs) of patients undergoing endoscopic resections have been sparse. The aim of our study was the prospective assessment of the Gastrointestinal Quality of Life Inde...
Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death [0.03%]
术后饮酒显著增加肝性脑病和肝相关死亡风险
Caroline Schwarz,Andrea Kornfehl,Reema Abid et al.
Caroline Schwarz et al.
Background: Complications related to portal hypertension (PH) in patients with alcohol-related liver disease (ALD) can be controlled by transjugular intrahepatic portosystemic shunt (TIPS) placement; however, the impact o...
High Burden of Pancreatic Surgery for Intraductal Papillary Mucinous Neoplasia With Low-Grade Dysplasia and Benign Cysts: A Systematic Review and Meta-Analysis [0.03%]
低度不典型增生和良性胰腺导管内乳头状黏液性肿瘤的手术负担：系统评价和Meta分析
Samuel Tanner,Priyata Dutta,Elit Quingalahua et al.
Samuel Tanner et al.
Background: Intraductal papillary mucinous neoplasms with low-grade dysplasia (IPMNs w/LGD) and benign cysts, including serous cystadenomas (SCAs), are common pancreatic cystic lesions (PCLs) that are better managed conse...